Minireview

Success for gene therapy: render unto Caesar that which is Caesar’s
Jian Qiao, Rosa Maria Diaz and Richard G Vile

Address: Molecular Medicine Program and Department of Immunology, Guggenheim 18, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA.

Correspondence: Richard G Vile. E-mail: Vile.Richard@mayo.edu

Published: 29 July 2004

Genome Biology 2004, 5:237

The electronic version of this article is the complete one and can be found online at http://genomebiology.com/2004/5/8/237

© 2004 BioMed Central Ltd

Abstract

Reports that two young children developed leukemia after being treated for immunodeficiency with their own retrovirally modified bone-marrow cells delivered a severe blow to confidence in gene therapy as a treatment. Two reports, published since the trial was initiated, now take away some of the mystery as to why these events happened and allay fears for the safety of gene therapy across all therapeutic applications.

“Friends, Romans, countrymen, lend me your ears; I come to bury Caesar, not to praise him.

The evil that men do lives after them;
The good is oft interred with their bones;
So let it be with Caesar. The noble Brutus
Hath told you Caesar was ambitious;
If it were so, it was a grievous fault,
And grievously hath Caesar answer’d it.”

Mark Antony, in Julius Caesar by William Shakespeare.

Recent findings have shown that that two young children treated by gene therapy to reverse their profound immune deficiency developed leukemia as a direct result of the experimental protocol [1,2]. These reports follow the tragic death of a young man after treatment with an adenoviral vector [3] and a more generalized sense of disappointment that the seemingly over-ambitious aspirations of gene therapists have not lived up to expectations. Against this backdrop, it is easy to feel a certain comradeship with Mark Antony, as he prepared to deliver his oration for the assassinated Emperor Julius Caesar in Rome. Brutus had just finished justifying to the assembled masses the apparently compelling reasons for the recent assassination based upon fears that Caesar’s ambition had turned from nobility into dangerous liability. So it is now with gene therapy, where whispering voices suggest that the ambitions of this field have outstretched its capabilities. Even the likes of Mark Antony might struggle to marry compassionate appreciation of previous problems, which will no doubt recur, with the eloquence to convince an audience that this remains a discipline where remarkable advances have been achieved.

The leukemias induced in two of ten children treated with gene therapy for an immuno-deficiency syndrome came as a double dagger blow to the heart of the gene-therapy field. These children were born with X-linked severe combined immunodeficiency (SCID-X1), which is caused by the genetic loss of the gene encoding common γ chain of the interleukin-2 receptor (IL-2Rγc) in mature γδT cells. Bone-marrow stem cells from the ten children were removed and infected with a retroviral vector encoding IL-2Rγc [4]; the treated stem cells were then re-infused into the children with the hope that the stably expressed, and integrated, IL-2Rγc gene would restore immune function to T cells as they re-populated the patients, thereby conferring systemic immune competency. This would permit the children, if all went well, to lead a life free of intensive quarantine [4]. But three years after the therapy was administered two of the children developed T-cell leukemia [1,2]. Not only did the leukemias originate from the re-infused T cells, but it has become clear that the integration of the retroviral vector was itself a major driver
in the evolution of the leukemic phenotype [2]. In particular, the leukemic cells from both patients had integrations of the vector very close to a cellular gene called \textit{LMO2} [2], deregulation of which has been observed in human T-cell leukemias [5].

As distressing as these reports have been, there is a second reason for profound disappointment at the outcome of the SCID-X1 trials. The findings of treatment-induced disease have inevitably deflected what was beginning to build into huge elation at the fact that, in 9 out of 10 of the treated children, the therapy had really worked [6]. This trial did, and still does, represent a truly remarkable triumph as the first unequivocal success for gene therapy. Many of the treated children have been able to resume normal lives outside of isolation and their prospects continue to be good. The finding that gene therapy had converted a severe immune-deficiency syndrome into a leukemia is therefore a particularly unwelcome diversion from what would otherwise be banner headlines stating that gene therapy is finally delivering on its medical promise.

Is it yet possible to change the perception that success can only go hand in hand with harm, as in the SCID trial, for any gene-therapy endeavor in the future? What would it take to reverse the tide of opinion mounting against the over-reaching ambition of gene therapy? One way to change opinions would be to obtain evidence for a uniqueness and specificity associated with these adverse clinical events, so as to suggest that they do not represent the inevitable face of things to come for any protocol involving gene transfer. Such evidence (to sway lingering Brutus-like assassins) has now come in the form of molecular characterization of the etiology of the leukemias in the two affected children [5,7] and an insightful study showing why they were not predicted earlier [8].

One of the big mysteries has been why the adverse events had not been predicted by the numerous pre-clinical studies for the relevant gene therapy trial. A large part of the answer came in a study reported in 2002 [8], which was, unfortunately, well after initiation of the trial [4]. The 2002 short report from Li \textit{et al.} [8] described the development of a similar leukemia in mice following gene transfer of a retroviral vector into bone-marrow-derived stem cells (Figure 1). There were two key aspects of novelty in this report, which explain why the phenomenon had not been seen before in the pre-clinical studies supporting the safety of the strategy used in the children with SCID. The authors used a retroviral vector to infect bone-marrow cells and re-infused them back into immunodeficient mice - with obvious parallels to the human clinical trials that had started a year or so earlier. In these re-infused mice, no leukemia was observed (Figure 1a). But because the lifetime of a single mouse may not be long enough to observe the evolution of fully transforming events - which are known to require co-operation between changes in multiple genes - the authors also serially transplanted the adoptively transferred bone marrow into a further irradiated (immune-deficient) recipient. Within 22 weeks of the passage from mouse to mouse, all the animals that received the secondary transplant developed hematopoietic disorders, and 60% developed an acute myeloid leukemia (Figure 1b).

These experiments included two critical factors that had not been tested together prior to initiation of the clinical trials. The first was that the life time of the transduced, reconstituted cells was extended beyond a single mouse’s lifetime, allowing observation of slow-developing, accumulating and co-operating mutations; and the second factor was that the modified marrow cells were re-infused into an immunologically depleted cell compartment. Homeostatic expansion of the cells was, therefore, both possible and inevitable [9], allowing for greater proliferation of the transduced cell population and the subsequent accumulation of additional genetic ‘hits’ leading to transformation (Figure 1c). The authors showed that the transgene that had been present in the retroviral vector - the \textit{dLNGFR} gene - was critical to the development of disease. The \textit{dLNGFR} gene is commonly used as a marker gene for such studies but - and with significant similarities to the \textit{IL-2Ryc} gene used in the human SCID trials - it is also a growth-factor receptor that could signal potentially transforming growth signals to transduced cells. Other marker genes used in the same protocol did not induce leukemic expansion of infected cells. Also, in a parallel to the findings from the SCID trial that were soon to emerge [2], all of the mouse leukemias contained a vector integrated into a single genetic locus: the murine \textit{Evil} gene (Figure 1c) [8]. Thus, Li \textit{et al.} [8] report a retroviral vector-induced leukemia that is dependent upon first, the transgene carried by the vector; second, the site of integration into the genome of transduced marrow progenitor cells; and third, a state of immune deficiency in the recipient hosts resulting in forced expansion of the transduced T-cell population (Figure 1).

Insertional mutagenesis, in which a promoter or enhancer in the vector transactivates the expression of an adjoining proto-oncogene, or in which the vector itself inactivates a tumor-suppressor gene, has long been viewed suspiciously as an unwelcome result of the use of any integrating vector [10]. The frequency of insertional mutagenesis is, however, predicted to be very low and so it has not been seen as a barrier to the use of such replication-defective vectors in clinical trials [10-12]. Nonetheless, even the most committed retrovirologist cannot fail to be concerned at a frequency of two insertional mutagenesis-induced leukemias in a group of ten subjects [1]. Therefore, while in no way belittling the significance of a second patient developing a leukemia, the finding that the etiology of the disease in the second patient was also associated with the same \textit{LMO2} gene paradoxically gave some reassurance [2]. Given the large range of known T-cell proto-oncogenes, the fact that both cases turned out to have integration sites around the same cellular gene argues strongly that the events were disease-, protocol-, and probably cell-type-specific.
as theoretically and mechanistically argued by McCormack and Rabbitts [5]. This suggestion implies that such adverse events are not necessarily to be expected following the use of retroviral vectors in all contexts, an important get-out clause for the survival of retroviruses as viable vectors.

The strength of this argument was confirmed recently by a study driven by the gift of hindsight, in which a search of a mouse retrovirus-tagged genomic database, containing insertion-site data from in excess of 3,000 retroviral-induced hematopoietic tumors, revealed records of two leukemias associated with insertion at the Lmo2 gene [7]. One leukemia had a retroviral insertion both in the Lmo2 gene and in the IL-2Rγc gene - precisely the gene combination involved in the SCID trial leukemia cases (Figure 2a). The chances that the leukemic murine cells would have retroviral...
insertions at both genes without them being involved in the leukemogenesis are minimal. The authors therefore suggest that these data show highly persuasive evidence that the \( IL-2R\gamma \) and \( Lmo2 \) genes can co-operate in the formation of leukemias (Figure 2a) [7], a proposal that now has considerable mechanistic support [5]. It is only a very short step to connect the introduction of the \( IL-2R\gamma \) gene within a retroviral vector that also happens to integrate close to the \( Lmo2 \) locus. As in the precursors to the murine leukemic cells, additional mutations were presumably required in order to accumulate sufficient signals for complete leukemogenesis. For these mutations to occur, the precursor pre-malignant cells would have to undergo multiple cell divisions. The fact that the patients were immune-deficient provided a fertile environment for homeostatic expansion of these cells, allowing them the time and immunological space required to acquire the extra mutations to allow emergence of a leukemic clone, just as demonstrated in the study by Li et al. [8]. Importantly, it was only the findings depicted in (b) that allowed the retrospective analysis shown in (a) to take place. At the time of initiation of the SCID trial, there was no way to predict that the use of the \( IL-2R\gamma \) therapeutic transgene would lead to the predisposing oncogenic cooperation with the \( LMO2 \) gene [5].

So why are these combined results of such encouragement despite being against the backdrop of some potentially tragic findings? First, they give us confidence that the use of retroviral, or integrating, vectors for transduction of most cell types is unlikely to cause cancer at a rate anywhere near the 20% (or, it is still possible, higher) seen in the SCID trial. Only under specific circumstances of co-operation between the vector-encoded gene, the insertion site and the ability of the transduced cells to expand in the patient, is there likely to be a significant risk of oncogenesis. Second, the findings indicate helpful ways in which vectors can be improved for future clinical development: the inclusion of suicide genes into the vectors would help in deleting any leukemic cells that might develop; the exposure of fewer stem cells to the vector, or inserting fewer copies per cell, will reduce the chances of leukemogenic clones developing; and other changes in vector design could be made to reduce the effects of transactivation of cellular proto-oncogenes. Third, they demonstrate that animal models can be developed that would more accurately predict the risks associated with protocols involving gene transfer into stem cells. Fourth, and perhaps most importantly, the data demonstrate that
the adverse clinical events seen in the two patients with SCID are fully understandable in terms of the specific protocol used. This makes the events no more sinister to the eventual successful development of gene transfer as a therapeutic modality than the many thousands of adverse events, including fatalities, that have characterized the development of other successful drugs.

Could the leukemias that developed in the children in the SCID trial have been predicted in the light of this knowledge? Possibly, but only if the clinical trials had been delayed until the implications of the model reported by Li et al. [8] were available, and if the database search performed by the Copeland group [7] had been carried out prospectively instead of retrospectively. But Rome was not built in a day. It would be ludicrous to suggest that the clinical trial should have been delayed in the hope that (unknown) critical pieces of data would emerge at a later date: to do so would mean that no new therapy would ever go into patient trials. And, over and above all other arguments, there is one that sometimes seems to be missed. If the clinical trials of the SCID infants had been delayed, what would have become of those children - including the two who developed leukemias that have been well controlled (at least so far) - who currently live a quality of life way beyond that which they would have been granted in the absence of the gene transfer therapy?

“I speak not to disprove what has happened,
But here I am to speak what I do know.
You all did love Caesar once, not without cause:
What cause withholds you then, to support him now?
O judgment! thou art fled to brutish beasts,
And men have lost their reason. Bear with me”

Mark Antony, in Julius Caesar by William Shakespeare.

References
1. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulfraat N, Mclnreyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New Engl J Med 2003, 348:255-256.
2. Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack MP, Wulfraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, et al.: LMO2-associated clonal T cell proliferations in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
3. Marshall E: Gene therapy death prompts review of adenovirus vector. Science 1999, 286:2244-2245.
4. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, et al.: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288:669-672.
5. McCormack MP, Rabbits TR: Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004, 350:913-922.
6. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bounaud C, Hue C, De Villartay JP, Thrasher AJ, Wulfraat N, Sorensen R, Dupuis-Girod S, et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002, 346:1185-1193.
7. Davé UP, Jenkins NA, Copeland NG: Gene therapy insertional mutagenesis insights. Science 2004, 303:333.
8. Li Z, Dullmann J, Shiedlineier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahler A, Frank O, et al.: Murine leukemia induced by retroviral gene marking. Science 2002, 296:497.
9. Mackall CL, Hakim FT, Gress RE: Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol 1997, 9:339-346.
10. Cornetta K, Morgan RA, Anderson WF: Safety issues related to retroviral-mediated gene transfer in humans. Hum Gene Ther 1991, 2:5-14.
11. Donahue RE, Kessler SW, Bodine D, McDonagh K, Dunbar C, Goodman S, Agricola B, Byrne E, Raffeld M, Moen R, et al.: Helper virus induced T-cell lymphoma in non human primates after retroviral mediated gene transfer. J Exp Med 1992, 176:1125-1135.
12. Anderson WF: What about those monkeys that got T-cell lymphoma? Hum Gene Ther 1993, 4:1-2.